# About TB-500 Store: An Independent Research Digest on the TB-500 Literature

> About TB-500 Store: an independent editorial project that summarizes the peer-reviewed research on TB-500 and thymosin beta-4. Not a clinic, not a vendor, not a prescription service.

What this site is, what the word in its name does and does not mean, and the standard every claim on it is held to.

## What this site is

TB-500 Store is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 and its parent protein, thymosin beta-4. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site reads the published record the way an instrument reads a signal: one mechanism traced from the actin-binding motif to tissue-repair outcomes, each finding logged with its evidence class, and the regulatory status stated present-tense. Every quantitative claim is tied to a numbered citation you can verify.

## What "Store" means here

The word "store" in the domain is editorial framing, not a claim about services. This site stores and organizes the research record on TB-500 — it is a repository of the literature, not a shop. Nothing is for sale here, nothing is dispensed, and no checkout, cart, or price appears anywhere on the site. The negative-space register of the design is deliberate: a research console, not a storefront.

We are explicit about this because the name could be read either way. Read it the way we mean it: a place the TB-500 literature is kept, sorted, and cited — a curated archive of what the studies measured.

## The standard we hold to

Three rules govern the content. First, the fragment-versus-parent-protein distinction is never blurred: where a finding was measured on the `~4963 Da` thymosin beta-4 protein rather than the `~889 Da` `Ac-LKKTETQ` heptapeptide marketed as TB-500, we say so [5]. Second, we describe what was administered to which species at which dose by which route — never a dose for a person, because the compound is not intended for human consumption [16]. Third, we state the honest gaps as plainly as the findings: there are no completed controlled human trials of the fragment, and the tumor and angiogenesis signal is unresolved [11][9].

The regulatory facts on the [TB-500 legal status](/legal-status) page are drawn from an audited reference and cited to the FDA, stated present-tense, with no future agency action presented as a certainty.

---

TB-500 Store runs the thymosin beta-4 literature as a single luminous pipeline — the Ac-LKKTETQ fragment traced from actin binding to tissue repair, every full-length-protein substitution flagged in line, the empty human-trial node left lit, and FDA's 503A standing read before anything else; a research repository, not a clinic, a vendor, or a prescription.